2014.
Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.
Since the announcement as of 7 August 2014, the following transactions have been made under the programme:
7 August 2014 230,000 248.99 57,267,102
8 August 2014 210,000 244.58 51,362,220
11 August 2014 250,000 248.38 62,095,375
12 August 2014 250,000 246.35 61,587,225
13 August 2014 210,000 245.75 51,607,500
14 August 2014 210,000 246.79 51,825,837
15 August 2014 260,000 249.11 64,768,054
Accumulated under the programme 1,620,000 400,513,313
Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale
by Novo Nordisk of 93,975 B shares in the period from 7 August 2014 to 15 August
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 50 / 2014
Page 2 of 2
2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 36,267,039 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 15 August 2014, Novo Nordisk has repurchased a total of 33,357,995 B shares equal to a transaction value of DKK
8,105,031,812.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately
40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further informationMedia: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 50 / 2014
distributed by |